Area of research
Infectious Diseases · Epidemiology
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies, SARS-CoV-2 detection and testing, and Respiratory viral infections research.
Differential protection against SARS-CoV-2 reinfection pre- and post-Omicron
Assessing healthy vaccinee effect in COVID-19 vaccine effectiveness studies: a national cohort study in Qatar
Effectiveness of two and three doses of COVID-19 mRNA vaccines against infection, symptoms, and severity in the pre-omicron era: A time-dependent gradient
Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study
Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study
Short- and longer-term all-cause mortality among SARS-CoV-2- infected individuals and the pull-forward phenomenon in Qatar: a national cohort study
Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar
Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar
Coronavirus Disease 2019 Disease Severity in Children Infected With the Omicron Variant
Duration of immune protection of SARS-CoV-2 natural infection against reinfection
Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections
Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage
Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study
COVID-19 disease severity in persons infected with the Omicron variant compared with the Delta variant in Qatar
Effects of BA.1/BA.2 subvariant, vaccination and prior infection on infectiousness of SARS-CoV-2 omicron infections
COVID-19 Disease Severity in Persons Infected With Omicron BA.1 and BA.2 Sublineages and Association With Vaccination Status
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar
SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy
Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar
Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic
Severity of Illness in Persons Infected With the SARS-CoV-2 Delta Variant vs Beta Variant in Qatar
Outcomes Among Patients with Breakthrough SARS-CoV-2 Infection After Vaccination
Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar
SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals
Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19
Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses
SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar
One Year of SARS-CoV-2: Genomic Characterization of COVID-19 Outbreak in Qatar
SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar